April 2024
1. NIERENGARTEN MB
   Golidocitinib favorable for relapsed/refractory T-cell lymphoma.
   Cancer. 2024;130:1191-1192.
   

   >> Share

   
   
2. LI A, Yi H, Deng S, Ruan M, et al
   The genetic landscape of histologically transformed marginal zone lymphomas.
   Cancer. 2024;130:1246-1256.
   

   >> Share

   
   
3. GIRI S, Harmon C, Landier W, Chen Y, et al
   Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
   Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
   

   >> Share

   
   February 2024
4. WU S, Rhee JW, Iukuridze A, Bosworth A, et al
   Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
   Cancer. 2024 Feb 15. doi: 10.1002/cncr.35252.
   

   >> Share

   
   
5. TZANKOV A, Tatarczuch M
   Time to Be Launched 1 auXiliary Risk strat1fier in marginal zone lymphoma transformation: TBL1XR1.
   Cancer. 2024 Feb 14. doi: 10.1002/cncr.35246.
   

   >> Share

   
   December 2023
6. DAI L, Chen H, Tan Q, Wang Y, et al
   Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
   Cancer. 2023 Dec 22. doi: 10.1002/cncr.35158.
   

   >> Share

   
   
7. CHU Y, Liu Y, Yu Z, Zhan L, et al
   Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
   Cancer. 2023 Dec 2. doi: 10.1002/cncr.35137.
   

   >> Share

   
   November 2023
8. GORDON MJ, Feng L, Strati P, Lee HJ, et al
   Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
   Cancer. 2023 Nov 20. doi: 10.1002/cncr.35114.
   

   >> Share

   
   
9. NIERENGARTEN MB
   New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
   Cancer. 2023;129:3356.
   

   >> Share

   
   October 2023
10. NIERENGARTEN MB
    ZUMA-7 trial shows the value of axicabtagene ciloleucel for early relapsed B-cell lymphoma.
    Cancer. 2023;129:2926.
    

    >> Share

    
    August 2023
11. BAIREY O, Taliansky A, Glik A, Amiel A, et al
    A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
    Cancer. 2023 Aug 12. doi: 10.1002/cncr.34985.
    

    >> Share

    
    July 2023
12. WADHWA A, Lim S, Dai C, Daniels G, et al
    Assessment of longitudinal changes in body composition of children with lymphoma and rhabdomyosarcoma.
    Cancer. 2023 Jul 11. doi: 10.1002/cncr.34936.
    

    >> Share

    
    May 2023
13. BAEK GT, Huang IJ, Gopal AK
    Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Cancer. 2023 May 19. doi: 10.1002/cncr.34816.
    

    >> Share

    
    
14. OERLEMANS S, Efficace F, Kyriakou C, Freitas AC, et al
    International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
    Cancer. 2023 May 19. doi: 10.1002/cncr.34822.
    

    >> Share

    
    
15. NIERENGARTEN MB
    Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:1466.
    

    >> Share

    
    
16. NIERENGARTEN MB
    FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.
    Cancer. 2023;129:1465-1466.
    

    >> Share

    
    March 2023
17. AFIFY ZAM, Taj MM, Orjuela-Grimm M, Srivatsa K, et al
    Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Cancer. 2023;129:780-789.
    

    >> Share

    
    February 2023
18. CHAKRABARTI D, Brahma Bhatt ML
    Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34712.
    

    >> Share

    
    
19. ALEMAN BMP, Krul IM, Janus CPM, van der Maazen RWM, et al
    Reply to "Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?".
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34713.
    

    >> Share

    
    
20. QUEUDEVILLE M, Stein AS, Locatelli F, Ebinger M, et al
    Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34667.
    

    >> Share

    
    
21. CHO J, Kim E, Yoon SE, Kim SJ, et al
    TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34698.
    

    >> Share

    
    
22. ALLEN PB, McCook-Veal AA, Switchenko JM, Paulino DM, et al
    Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
    Cancer. 2023;129:541-550.
    

    >> Share

    
    
23. BODDU PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, et al
    A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Cancer. 2023;129:580-589.
    

    >> Share

    
    
24. PENG Y, Zhao Q, Liao Z, Ma Y, et al
    Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Cancer. 2023 Feb 7. doi: 10.1002/cncr.34664.
    

    >> Share

    
    January 2023
25. WONG CI, Vannatta K, Gilleland Marchak J, Quade EV, et al
    Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment.
    Cancer. 2023 Jan 27. doi: 10.1002/cncr.34651.
    

    >> Share

    
    
26. GUIDETTI A, Dodero A, Lorenzoni A, Pizzamiglio S, et al
    Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
    Cancer. 2023;129:255-263.
    

    >> Share

    
    December 2022
27. GAO Y, Liu Y, Wang Y, Zhang Q, et al
    Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
    Cancer. 2022 Dec 21. doi: 10.1002/cncr.34544.
    

    >> Share

    
    November 2022
28. DUDLEY IM, Sunguc C, Heymer EJ, Winter DL, et al
    Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.
    Cancer. 2022 Nov 29. doi: 10.1002/cncr.34561.
    

    >> Share

    
    
29. YANG J, Yu L, Man J, Chen H, et al
    Immune scoring model based on immune cell infiltration to predict prognosis in diffuse large B-cell lymphoma.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34519.
    

    >> Share

    
    October 2022
30. KRUL IM, Boekel NB, Kramer I, Janus CPM, et al
    Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
    Cancer. 2022 Oct 25. doi: 10.1002/cncr.34464.
    

    >> Share

    
    
31. PATEL PA, DeGroote NP, Jackson K, Cash T, et al
    Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia.
    Cancer. 2022 Oct 13. doi: 10.1002/cncr.34476.
    

    >> Share

    
    
32. PATEL DA, Kahl BS
    Top advances in lymphoma for 2021.
    Cancer. 2022 Oct 6. doi: 10.1002/cncr.34483.
    

    >> Share

    
    
33. YANG Y, Wang JJ, Zhao RZ, Huang C, et al
    The value of routine bone marrow examination in patients with extranodal NK/T-cell lymphoma staged with PET/CT.
    Cancer. 2022 Oct 1. doi: 10.1002/cncr.34473.
    

    >> Share

    
    September 2022
34. HOLLEBECQUE A, Salvagni S, Plummer R, Niccoli P, et al
    Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
    Cancer. 2022;128:3185-3195.
    

    >> Share

    
    August 2022
35. MA S, Zhang B, Lu T, Li D, et al
    Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
    Cancer. 2022 Aug 6. doi: 10.1002/cncr.34405.
    

    >> Share

    
    
36. TAO R, Chen Y, Kim S, Ocier K, et al
    Mental health disorders are more common in patients with Hodgkin lymphoma and may negatively impact overall survival.
    Cancer. 2022 Aug 2. doi: 10.1002/cncr.34359.
    

    >> Share

    
    July 2022
37. LU Z, Teng Y, Ning X, Wang H, et al
    Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.
    Cancer. 2022 Jul 25. doi: 10.1002/cncr.34375.
    

    >> Share

    
    April 2022
38. RAJAMAKI A, Hujo M, Sund R, Prusila REI, et al
    Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34221.
    

    >> Share

    
    
39. GANGARAJU R, Davis ES, Bhatia S, Kenzik KM, et al
    Venous-thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma.
    Cancer. 2022 Apr 1. doi: 10.1002/cncr.34210.
    

    >> Share

    
    
40. HUTCHESON KA, Barbon CEA, Alvarez CP, Warneke CL, et al
    Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria: Validation of DIGEST version 2.
    Cancer. 2022;128:1458-1466.
    

    >> Share

    
    February 2022
41. CHOW EJ, Aplenc R, Vrooman LM, Doody DR, et al
    Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
    Cancer. 2022;128:788-796.
    

    >> Share

    
    
42. TORKA P, Akhtar OS, Reddy NM, Baysal BE, et al
    Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study.
    Cancer. 2022 Feb 14. doi: 10.1002/cncr.34106.
    

    >> Share

    
    January 2022
43. 
    Erratum to "Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation".
    Cancer. 2022 Jan 27. doi: 10.1002/cncr.33973.
    

    >> Share

    
    
44. NOONE AM, Pfeiffer RM, Schaubel DE, Dorgan JF, et al
    Life-years lost due to cancer among solid organ transplant recipients in the United States, 1987 to 2014.
    Cancer. 2022;128:150-159.
    

    >> Share

    
    December 2021
45. BACHIASHVILI K, Francisco L, Chen Y, Bosworth A, et al
    Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma.
    Cancer. 2021 Dec 28. doi: 10.1002/cncr.34072.
    

    >> Share

    
    
46. WONG SM, Ajjamada L, Weiss AC, Prakash I, et al
    Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
    Cancer. 2021 Dec 17. doi: 10.1002/cncr.34065.
    

    >> Share

    
    
47. UNGER JM, Beauchemin M, Hershman DL
    Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.
    Cancer. 2021;127:4574-4584.
    

    >> Share

    
    November 2021
48. WADHWA A, Adams KM, Dai C, Richman JS, et al
    Association between body composition and chemotherapy-related toxicity in children with lymphoma and rhabdomyosarcoma.
    Cancer. 2021 Nov 30. doi: 10.1002/cncr.34043.
    

    >> Share

    
    
49. LEUPIN N, Zinzani PL, Morschhauser F, Dalle S, et al
    Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
    Cancer. 2021 Nov 2. doi: 10.1002/cncr.34005.
    

    >> Share

    
    October 2021
50. NERICH V, Guyeux C, Henry-Amar M, Couturier R, et al
    Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.
    Cancer. 2021 Oct 4. doi: 10.1002/cncr.33938.
    

    >> Share

    
    September 2021
51. KAHN JM, Maguire FB, Li Q, Abrahao R, et al
    Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population-based study.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33868.
    

    >> Share

    
    August 2021
52. KLISOVIC RB, Leung WH, Brugger W, Dirnberger-Hertweck M, et al
    A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33796.
    

    >> Share

    
    July 2021
53. HU B, Boselli D, Pye LM, Chen T, et al
    Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma.
    Cancer. 2021 Jul 21. doi: 10.1002/cncr.33779.
    

    >> Share

    
    
54. JUWEID ME, Mueller M, Alhouri A, A-Risheq MZ, et al
    Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Cancer. 2021 Jul 19. doi: 10.1002/cncr.33772.
    

    >> Share

    
    June 2021
55. EL-GALALY TC, Ovlisen AK, Cheah CY
    Routine imaging for disease surveillance in follicular lymphoma-To comfort the patients or their doctors?
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33659.
    

    >> Share

    
    
56. GOLDMAN ML, Mao JJ, Strouse CS, Chen W, et al
    Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33660.
    

    >> Share

    
    November 2020
57. TOPP MS, Gokbuget N, Zugmaier G, Stein AS, et al
    Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Cancer. 2020 Nov 3. doi: 10.1002/cncr.33298.
    

    >> Share

    
    June 2020
58. KARSCHNIA P, Batchelor TT, Jordan JT, Shaw B, et al
    Primary dural lymphomas: Clinical presentation, management, and outcome.
    Cancer. 2020;126:2811-2820.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share